Wasatch Advisors LP Takes $3.36 Million Position in Eton Pharmaceuticals, Inc. $ETON

Wasatch Advisors LP bought a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 92,742 shares of the company’s stock, valued at approximately $3,357,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Opaleye Management Inc. lifted its position in shares of Eton Pharmaceuticals by 0.3% during the 2nd quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after buying an additional 7,930 shares during the last quarter. EcoR1 Capital LLC raised its stake in Eton Pharmaceuticals by 7.0% during the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after acquiring an additional 141,394 shares in the last quarter. Vanguard Group Inc. lifted its position in Eton Pharmaceuticals by 2.4% in the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after acquiring an additional 31,942 shares during the last quarter. State Street Corp boosted its stake in Eton Pharmaceuticals by 14.5% in the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock valued at $8,488,000 after acquiring an additional 63,480 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock worth $4,620,000 after purchasing an additional 217,042 shares in the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $65 price target for Eton Pharmaceuticals (ETON). The target implies meaningful upside from recent trading levels and indicates confidence in the company’s longer-term growth prospects.
• Positive Sentiment: The firm expects earnings to strengthen through 2027, forecasting EPS of $0.26 in Q1, $0.30 in Q2, $0.36 in Q3 and $0.35 in Q4. These estimates suggest improving profitability beyond 2026.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The figures appear unreliable or incomplete, so they provide little actionable information about trading sentiment.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to $0.52 from $0.68. Quarterly estimates were also reduced: Q2 EPS to $0.11 from $0.15, Q3 to $0.17 from $0.23 and Q4 to $0.19 from $0.25. The revisions point to weaker-than-previously-expected near-term earnings and may weigh on the shares.
• Negative Sentiment: The updated FY2026 forecast is below the broader consensus estimate of $0.75 per share, increasing the risk of future estimate cuts or earnings-related disappointment.

Insider Transactions at Eton Pharmaceuticals

In related news, insider David Krempa sold 19,679 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the completion of the sale, the insider owned 25,249 shares in the company, valued at $794,586.03. This trade represents a 43.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. HC Wainwright lifted their price target on Eton Pharmaceuticals from $57.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Friday, July 17th. Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group assumed coverage on shares of Eton Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Eton Pharmaceuticals Stock Down 1.1%

Eton Pharmaceuticals stock opened at $41.58 on Thursday. The stock has a 50 day moving average of $38.23 and a two-hundred day moving average of $28.20. Eton Pharmaceuticals, Inc. has a twelve month low of $14.27 and a twelve month high of $50.18. The stock has a market capitalization of $1.14 billion, a price-to-earnings ratio of -593.92 and a beta of 0.86. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The firm had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $22.31 million. As a group, research analysts expect that Eton Pharmaceuticals, Inc. will post 0.67 earnings per share for the current year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.